Lanzhou Foci Pharmaceutical Co Ltd (002644) — Strategic Asset Allocation Index
Lanzhou Foci Pharmaceutical Co Ltd (002644) has a Strategic Asset Allocation Index of 59.1% as of September 2023. Strategic assets (PP&E of CN¥1.04 Billion plus long-term investments of CN¥-) total CN¥1.04 Billion, measured against net assets of CN¥1.77 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Lanzhou Foci Pharmaceutical Co Ltd Strategic Asset Allocation Index (2008–2021)
This chart shows how Lanzhou Foci Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 14 annual periods from 2008 to 2021. As of September 2023, the index stands at 59.1%, representing strategic assets of CN¥1.04 Billion against net assets of CN¥1.77 Billion CNY. Explore 002644 cash flow metrics to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Lanzhou Foci Pharmaceutical Co Ltd (2008–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Lanzhou Foci Pharmaceutical Co Ltd from 2008 to 2021, covering 14 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Lanzhou Foci Pharmaceutical Co Ltd market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 67.1% | CN¥1.09 Billion | CN¥1.09 Billion | CN¥- | CN¥1.63 Billion | ▼ -2.9 pp |
| 2020 | 70.0% | CN¥1.11 Billion | CN¥1.11 Billion | CN¥- | CN¥1.59 Billion | ▲ +5.5 pp |
| 2019 | 64.5% | CN¥971.63 Million | CN¥971.63 Million | CN¥- | CN¥1.51 Billion | ▼ -23.4 pp |
| 2018 | 87.9% | CN¥1.27 Billion | CN¥1.22 Billion | CN¥42.50 Million | CN¥1.44 Billion | ▲ +6.9 pp |
| 2017 | 80.9% | CN¥1.10 Billion | CN¥1.10 Billion | CN¥- | CN¥1.36 Billion | ▲ +44.4 pp |
| 2016 | 36.5% | CN¥471.22 Million | CN¥471.22 Million | CN¥- | CN¥1.29 Billion | ▲ +21.3 pp |
| 2015 | 15.2% | CN¥187.78 Million | CN¥187.78 Million | CN¥- | CN¥1.23 Billion | ▼ -7.5 pp |
| 2014 | 22.7% | CN¥167.04 Million | CN¥167.04 Million | CN¥- | CN¥735.22 Million | ▼ -19.1 pp |
| 2013 | 41.8% | CN¥294.12 Million | CN¥294.12 Million | CN¥- | CN¥703.37 Million | ▲ +2.2 pp |
| 2012 | 39.6% | CN¥267.76 Million | CN¥267.76 Million | CN¥- | CN¥675.53 Million | ▲ +11.4 pp |
| 2011 | 28.3% | CN¥183.16 Million | CN¥183.16 Million | CN¥- | CN¥648.08 Million | ▼ -18.2 pp |
| 2010 | 46.5% | CN¥151.69 Million | CN¥151.69 Million | CN¥- | CN¥326.46 Million | ▼ -7.7 pp |
| 2009 | 54.2% | CN¥137.04 Million | CN¥137.04 Million | CN¥- | CN¥252.96 Million | ▼ -8.6 pp |
| 2008 | 62.7% | CN¥136.04 Million | CN¥136.04 Million | CN¥- | CN¥216.81 Million | — |